Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar;31(3):156-61.
doi: 10.1111/j.1365-3024.2008.01091.x.

Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni

G Ahmad  1 , W Torben, W Zhang, M Wyatt, A A Siddiqui
Affiliations

Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni

G Ahmad et al. Parasite Immunol. 2009 Mar.

Abstract

No effective vaccine exists for the human parasitic disease, schistosomiasis. We have targeted a functionally important antigen, Sm-p80 as a vaccine candidate because of its consistent immunogenicity, protective potential and important role in the immune evasion process. In this study we report that a Sm-p80-based DNA vaccine formulation confers 59% reduction in worm burden in mice. Animals immunized with Sm-p80-pcDNA3 exhibited a decrease in egg production by 84%. Sm-p80 DNA elicited strong immune responses that include IgG2A and IgG2B antibody isotypes in vaccinated animals. Splenocytes proliferated in response to Sm-p80 produced appreciably more Th1 response enhancing cytokines (IL-2, IFN-gamma) than Th2 response enhancing cytokines (IL-4, IL-10). These data reinforce the potential of Sm-p80 as an excellent vaccine candidate for schistosomiasis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Titers of anti-Sm-p80 antibodies in immunized mice. ELISA was performed with a pool of sera obtained by mixing equal volumes of serum collected from each mouse(biweekly) in their respective groups (VR1020 and Sm-p80-VR1020). IgG (A), IgG1 (B) IgG2a (C), IgG2b (D) IgG3 (E) IgM(F) and IgA (G).The value represent the mean of three experiments ± standard error. Statistic significance (P<0.05) are indicated by (*) compared with VR1020 control group.
Figure 1
Figure 1
Titers of anti-Sm-p80 antibodies in immunized mice. ELISA was performed with a pool of sera obtained by mixing equal volumes of serum collected from each mouse(biweekly) in their respective groups (VR1020 and Sm-p80-VR1020). IgG (A), IgG1 (B) IgG2a (C), IgG2b (D) IgG3 (E) IgM(F) and IgA (G).The value represent the mean of three experiments ± standard error. Statistic significance (P<0.05) are indicated by (*) compared with VR1020 control group.
Figure 1
Figure 1
Titers of anti-Sm-p80 antibodies in immunized mice. ELISA was performed with a pool of sera obtained by mixing equal volumes of serum collected from each mouse(biweekly) in their respective groups (VR1020 and Sm-p80-VR1020). IgG (A), IgG1 (B) IgG2a (C), IgG2b (D) IgG3 (E) IgM(F) and IgA (G).The value represent the mean of three experiments ± standard error. Statistic significance (P<0.05) are indicated by (*) compared with VR1020 control group.
Figure 1
Figure 1
Titers of anti-Sm-p80 antibodies in immunized mice. ELISA was performed with a pool of sera obtained by mixing equal volumes of serum collected from each mouse(biweekly) in their respective groups (VR1020 and Sm-p80-VR1020). IgG (A), IgG1 (B) IgG2a (C), IgG2b (D) IgG3 (E) IgM(F) and IgA (G).The value represent the mean of three experiments ± standard error. Statistic significance (P<0.05) are indicated by (*) compared with VR1020 control group.
Figure 2
Figure 2
Levels of cytokine production by splenocytes after 48 hr stimulation with recombinant Sm-p80 in vitro. Groups of mice were inoculated with VR1020 and Sm-p80-VR1020. Data are shown as mean ± S.D. Statistical significance (P<0.05) are indicated by (*) compared with VR1020 control group using independent sample t- test.
Figure 3
Figure 3
RT-PCR for cytokine expression by splenocytes after 24 hr stimulation with recombinant Sm-p80 in vitro. Panels 1, and 3, control groups inoculated with VR1020; Panels 2, 4, experimental groups inoculated with Sm-p80-VR1020. 1, 2, medium control; 3,4, splenocytes stimulated with recombinant Sm-p80.
Figure 4
Figure 4
Fold relative difference of cytokine mRNA level by splenocytes after 24 hr stimulation with recombinant Sm-p80 in vitro. The fold difference was calculated by comparing the differences in the message levels of the control group (VR1020) with the experimental group (Sm-p80-VR1020) after standardization using respective GAPDH.
See this image and copyright information in PMC

References

    1. Berriman M, Haas BJ, LoVerde PT, et al. The genome of the blood fluke Schistosoma mansoni. Nature. 2009;460:352–358. - PMC - PubMed
    1. Hotez PJ, Molyneux DH, Fenwick A, et al. Control of neglected tropical diseases. N Engl J Med. 2007;357:1018–1027. - PubMed
    1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6:411–425. - PubMed
    1. Young BW, Podesta RB. Complement and 5-HT increase phosphatidylcholine incorporation into the outer bilayers of Schistosoma mansoni. J Parasitol. 1986;72:802–803. - PubMed
    1. Ahmad G, Torben W, Zang W, Matt W, Siddiqui AA. Sm-p80 based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni,. Parasite Immunol. 2008;31:156–161. - PMC - PubMed

Publication types